RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Royalty Pharma plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$60.27−0.69 (-1.13%)

Close on Oct 19, 2026

Market cap: $33.56B
P/E (TTM): 34.2
Dividend yield: –

Royalty Pharma plc cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Stock-Based Compensation	290	2.34	2.36	2.17	2.44	5.43	0	0
Other Non-Cash Items	-13	-1.11	-21	-11	-4.46	-9.62	2.12	7.77
Change in Accounts Payable	-14	-2.29	6.24	2.29	-4.59	-0.77	6.50	1.35
Operating Cash Flow	2,490	2,769	2,988	2,144	2,018	2,035	1,667	1,618
Acquisitions	-74	0	0	–	–	–	–	–
Purchase of Investments	-175	0	0	-235	-1,197	-1,705	-817	0
Sale & Maturity of Investments	0	0	24	792	1,598	815	725	0
Other Investing Activities	-8.95	2.04	-2.04	0	0	–	–	–
Investing Cash Flow	-1,614	-2,678	-2,073	-1,029	-1,870	-2,759	-2,154	303
Share Repurchases	-1,227	-230	-305	0	0	0	-4.27	0
Debt Issued	–	–	–	0	1,273	11,891	0	0
Debt Repaid	–	–	–	0	0	-11,116	0	0
Other Financing Activities	-1.79	-9.03	0	0	–	–	–	–
Financing Cash Flow	-1,186	361	-2,149	-945	385	1,487	-1,192	-1,379
Net Change in Cash	-310	452	-1,234	170	532	762	-1,678	543
Interest Paid	276	160	169	170	130	103	255	268

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 59.6%
Net margin: 32.1%
Return on equity, FY2025: –

Financial strength

Current ratio: 2.80
Debt to equity: –
Debt to assets: 45.2%
Cash to current liabilities: 128.7%

Valuation

P/E ratio: 34.2
Price to sales: 13.24
Price to book: –
Dividend yield: –